| Literature DB >> 33845483 |
Alexey Stukalov1, Virginie Girault1, Vincent Grass1, Ozge Karayel2, Valter Bergant1, Christian Urban1, Darya A Haas1, Yiqi Huang1, Lila Oubraham1, Anqi Wang1, M Sabri Hamad1, Antonio Piras1, Fynn M Hansen2, Maria C Tanzer2, Igor Paron2, Luca Zinzula3, Thomas Engleitner4, Maria Reinecke5,6,7, Teresa M Lavacca1, Rosina Ehmann8,9, Roman Wölfel8,9, Jörg Jores10, Bernhard Kuster5,6,7, Ulrike Protzer1,9, Roland Rad4, John Ziebuhr11, Volker Thiel12,13, Pietro Scaturro1,14, Matthias Mann2, Andreas Pichlmair15,16.
Abstract
The emergence and global spread of SARS-CoV-2 has resulted in the urgent need for an in-depth understanding of molecular functions of viral proteins and their interactions with the host proteome. Several individual omics studies have extended our knowledge of COVID-19 pathophysiology1-10. Integration of such datasets to obtain a holistic view of virus-host interactions and to define the pathogenic properties of SARS-CoV-2 is limited by the heterogeneity of the experimental systems. Here we report a concurrent multi-omics study of SARS-CoV-2 and SARS-CoV. Using state-of-the-art proteomics, we profiled the interactomes of both viruses, as well as their influence on the transcriptome, proteome, ubiquitinome and phosphoproteome of a lung-derived human cell line. Projecting these data onto the global network of cellular interactions revealed crosstalk between the perturbations taking place upon infection with SARS-CoV-2 and SARS-CoV at different levels and enabled identification of distinct and common molecular mechanisms of these closely related coronaviruses. The TGF-β pathway, known for its involvement in tissue fibrosis, was specifically dysregulated by SARS-CoV-2 ORF8 and autophagy was specifically dysregulated by SARS-CoV-2 ORF3. The extensive dataset (available at https://covinet.innatelab.org ) highlights many hotspots that could be targeted by existing drugs and may be used to guide rational design of virus- and host-directed therapies, which we exemplify by identifying inhibitors of kinases and matrix metalloproteases with potent antiviral effects against SARS-CoV-2.Entities:
Mesh:
Substances:
Year: 2021 PMID: 33845483 DOI: 10.1038/s41586-021-03493-4
Source DB: PubMed Journal: Nature ISSN: 0028-0836 Impact factor: 49.962